Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma

Clinical Cancer Research

Volumn 16, Issue 22, 2010, Pages 5529-5538

  Kriegl, Lydia ^a   Jung, Andreas ^a   Engel, Jutta ^b   Jackstadt, Rene ^a   Gerbes, Alexander L ^b   Gallmeier, Eike ^b   Reiche, Jana A ^a   Hermeking, Heiko ^a   Rizzani, Antonia ^b   Bruns, Christiane J ^b   Kolligs, Frank T ^b   Kirchner, Thomas ^a   Göke, Burkhard ^b   De Toni, Enrico N ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; ARTICLE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SAMPLE;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

EID: 78349233558     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3403     Document Type: Article

References (37)

1. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-76.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135: 1972-83.
4. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725-33.
5. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8: 782-98.
6. Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets 2005;9:83-99.
7. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61.
8. De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by β-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008;14:4713-8.
9. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
10. Walczak H, Koschny R, Willen Daniela, et al. The TRAIL receptor-ligand system: biochemistry of apoptosis induction, therapeutic potential for cancer treatment and physiological functions. In: Debatin KM, Fulda S, editors. Apoptosis and cancer therapy. Weinheim: Wiley-VCH; 2006, p. 31-74.
11. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
12. Hirohashi S, Ishak K, Kojiro M. Hepatocellular carcinoma. In: Hamilton S, Aaltonen L, editors. World Health Organization classification of tumours: pathology and genetics tumours of the digestive system. Lyon: IARC Press; 2000, p. 159-72.
13. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
15. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982;38:933-42.
16. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
17. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50.
18. Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942-6.
19. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005;11:5188-94.
20. Strater J, Hinz U, Walczak H, et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002;8:3734-40.
21. Herr I, Schemmer P, Buchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007;46:266-74.
22. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-9.
23. van Noesel MM, van Bezouw S, Salomons GS, et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002;62:2157-61.
24. Chen XP, He SQ, Wang HP, Zhao YZ, Zhang WG. Expression of TNF-related apoptosis-inducing ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. World J Gastroenterol 2003;9:2433-40.
25. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008;6:1861-71.
26. Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 2005;12:94-7.
27. Grosse-Wilde A, Voloshanenko O, Bailey SL, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-10.
28. Ohira M, Ohdan H, Mitsuta H, et al. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006;82:1712-9.
29. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100. (Pubitemid 32095647)
30. Jeng YM, Hsu HC. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett 2002;181:205-8.
31. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9.
32. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 2008;27:490-8.
33. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005;62:165-86.
34. Merchant MS, Yang X, Melchionda F, et al. Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004;64:8349-56.
35. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
36. Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80.
37. Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007;46:1498-508.